| Budget Amount *help |
¥121,290,000 (Direct Cost: ¥93,300,000、Indirect Cost: ¥27,990,000)
Fiscal Year 2019: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2018: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2017: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2016: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2015: ¥28,470,000 (Direct Cost: ¥21,900,000、Indirect Cost: ¥6,570,000)
|
|---|
| Outline of Final Research Achievements |
Changes in higher epigenome of the host due to virus infection and interaction between virus and host epigenome were analyzed.The mechanism of higher epigenome operation was clarified, and based on these, the molecular basis of higher epigenome changes leading to the pathogenesis and severity of viral infections was elucidated using gene-deficient cells, mice, and mutant viruses.Next, we identified epigenomic modifications that lead to severe disease and explored their potential applications in early diagnosis and preemptive medicine.Furthermore, regarding epigenome modification involved in the pathogenesis, we searched for candidate compounds for anti-influenza drugs targeting this.Through the above, we aimed to acquire the academic base information for establishing a new treatment strategy for severe viral infections for which there is no effective treatment that leads to lifesaving.
|
